| DB ID | MyCo_2330 |
| Title | Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis |
| Year | 2011 |
| PMID | 21940419 |
| Fungal Diseases involved | Cryptococcal meningitis |
| Associated Medical Condition | HIV-AIDS |
| Genus | Cryptococcus |
| Species | spp. |
| Organism | Cryptococcus spp. |
| Ethical Statement | This study was approved by the Research Ethics Committee of the University of Cape Town, South Africa. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Urine |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GXM |
| Biomarker Full Name | Glucuronoxylomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | Sample collection was performed between March 2009 and November 2010 at GF Jooste Hospital, a public-sector adult referral hospital in Cape Town, South Africa. Paired blood and urine samples were collected from adult patients (³21 years), with a history of laboratory-confirmed HIV-associated cryptococcal disease within the preceding 2 years. GXM concentrations were determined in paired serum, plasma, and urine from 62 patients with active or recent CM, using a quantitative sandwich enzyme-linked immunosorbent assay (ELISA). |
| Cohort No. | 62 |
| Age Group | 34 |
| P Value | p<.001 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | 22 |
| Pathway | None |
| Disease Introduction Mechanism | Cryptococcal meningitis (CM) is estimated to kill more than 500 000 human immunodeficiency virus (HIV)– infected patients per year in Sub-Saharan Africa. With the evolving HIV epidemic, CM has emerged as the most frequent cause of adult meningitis in much of central and southern Africa, and outcomes with current optimal antifungal therapy are poor. Many deaths from CM may be preventable through early diagnosis and treatment. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA, Lateral Flow Assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
